A single immunization with spike-functionalized ferritin vaccines elicits neutralizing antibody responses against SARS-CoV-2 in mice

Development of a safe and effective SARS-CoV-2 vaccine is a public health priority. We designed subunit vaccine candidates using self-assembling ferritin nanoparticles displaying one of two multimerized SARS-CoV-2 spikes: full-length ectodomain (S-Fer) or a C-terminal 70 amino-acid deletion (SΔC-Fer). Ferritin is an attractive nanoparticle platform for production of vaccines and ferritin-based vaccines have been investigated in humans in two separate clinical trials. We confirmed proper folding and antigenicity of spike on the surface of ferritin by cryo-EM and binding to conformation-specific monoclonal antibodies. After a single immunization of mice with either of the two spike ferritin particles, a lentiviral SARS-CoV-2 pseudovirus assay revealed mean neutralizing antibody titers at least 2-fold greater than those in convalescent plasma from COVID-19 patients. Additionally, a single dose of SΔC-Fer elicited significantly higher neutralizing responses as compared to immunization with the spike receptor binding domain (RBD) monomer or spike ectodomain trimer alone. After a second dose, mice immunized with SΔC-Fer exhibited higher neutralizing titers than all other groups. Taken together, these results demonstrate that multivalent presentation of SARS-CoV-2 spike on ferritin can notably enhance elicitation of neutralizing antibodies, thus constituting a viable strategy for single-dose vaccination against COVID-19.

[1]  D. Weissman,et al.  SARS-CoV-2 mRNA Vaccines Foster Potent Antigen-Specific Germinal Center Responses Associated with Neutralizing Antibody Generation , 2020, Immunity.

[2]  E. Walsh,et al.  Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates , 2020, The New England journal of medicine.

[3]  Min Zheng,et al.  A systematic review of SARS-CoV-2 vaccine candidates , 2020, Signal Transduction and Targeted Therapy.

[4]  Ralf Bartenschlager,et al.  Structures and distributions of SARS-CoV-2 spike proteins on intact virions , 2020, Nature.

[5]  Lisa E. Gralinski,et al.  Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2 , 2020, Cell.

[6]  E. Walsh,et al.  Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults , 2020, Nature.

[7]  C. Hillyer,et al.  A novel receptor-binding domain (RBD)-based mRNA vaccine against SARS-CoV-2 , 2020, Cell Research.

[8]  Rebecca J. Loomis,et al.  SARS-CoV-2 mRNA Vaccine Design Enabled by Prototype Pathogen Preparedness , 2020, Nature.

[9]  D. Sheward,et al.  SARS-CoV-2 protein subunit vaccination elicits potent neutralizing antibody responses , 2020, bioRxiv.

[10]  V. Munster,et al.  ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques , 2020, Nature.

[11]  H. Schuitemaker,et al.  Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses , 2020, npj Vaccines.

[12]  Rebecca J. Loomis,et al.  Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates , 2020, The New England journal of medicine.

[13]  Nguyen H. Tran,et al.  Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial , 2020, The Lancet.

[14]  P. Dormitzer,et al.  Concurrent human antibody andTH1 type T-cell responses elicited by a COVID-19 RNA vaccine , 2020, medRxiv.

[15]  Caizheng Yu,et al.  Linear epitope landscape of the SARS-CoV-2 Spike protein constructed from 1,051 COVID-19 patients , 2020, Cell Reports.

[16]  D. Fremont,et al.  Neutralizing Antibody and Soluble ACE2 Inhibition of a Replication-Competent VSV-SARS-CoV-2 and a Clinical Isolate of SARS-CoV-2 , 2020, Cell Host & Microbe.

[17]  E. Walsh,et al.  Phase 1/2 Study to Describe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age: Interim Report , 2020, medRxiv.

[18]  Beata Turoňová,et al.  In situ structural analysis of SARS-CoV-2 spike reveals flexibility mediated by three hinges , 2020, Science.

[19]  Ralf Bartenschlager,et al.  SARS-CoV-2 structure and replication characterized by in situ cryo-electron tomography , 2020, Nature Communications.

[20]  Qiang Zhou,et al.  A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2 , 2020, Science.

[21]  R. Owens,et al.  Evaluation of the immunogenicity of prime-boost vaccination with the replication-deficient viral vectored COVID-19 vaccine candidate ChAdOx1 nCoV-19 , 2020, npj Vaccines.

[22]  R. Owens,et al.  Evaluation of the immunogenicity of prime-boost vaccination with the replication-deficient viral vectored COVID-19 vaccine candidate ChAdOx1 nCoV-19 , 2020, npj Vaccines.

[23]  C. Funk,et al.  A Snapshot of the Global Race for Vaccines Targeting SARS-CoV-2 and the COVID-19 Pandemic , 2020, Frontiers in Pharmacology.

[24]  D. Burton,et al.  Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model , 2020, Science.

[25]  C. Rice,et al.  Convergent Antibody Responses to SARS-CoV-2 in Convalescent Individuals , 2020, Nature.

[26]  Rebecca J. Loomis,et al.  SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness , 2020, bioRxiv.

[27]  L. Pirofski,et al.  Characterization of the SARS-CoV-2 S Protein: Biophysical, Biochemical, Structural, and Antigenic Analysis , 2020, bioRxiv.

[28]  G. Gao,et al.  Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2 , 2020, Cell.

[29]  D. Fremont,et al.  Neutralizing Antibody and Soluble ACE2 Inhibition of a Replication-Competent VSV-SARS-CoV-2 and a Clinical Isolate of SARS-CoV-2. , 2020, SSRN.

[30]  William J. Liu,et al.  A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2 , 2020, Nature.

[31]  Daniel W. Kulp,et al.  Immunogenicity of a DNA vaccine candidate for COVID-19 , 2020, Nature Communications.

[32]  V. Munster,et al.  ChAdOx1 nCoV-19 vaccination prevents SARS-CoV-2 pneumonia in rhesus macaques , 2020, bioRxiv.

[33]  J. Derisi,et al.  ReScan, a Multiplex Diagnostic Pipeline, Pans Human Sera for SARS-CoV-2 Antigens , 2020, Cell Reports Medicine.

[34]  C. Cunningham-Rundles,et al.  A serological assay to detect SARS-CoV-2 seroconversion in humans , 2020, Nature Medicine.

[35]  M. V. van Breemen,et al.  Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability , 2020, Science.

[36]  Daniel Wrapp,et al.  Site-specific glycan analysis of the SARS-CoV-2 spike , 2020, Science.

[37]  G. Nabel,et al.  Design of a broadly reactive Lyme disease vaccine , 2020, npj Vaccines.

[38]  G. Nabel,et al.  A respiratory syncytial virus (RSV) F protein nanoparticle vaccine focuses antibody responses to a conserved neutralization domain , 2020, Science Immunology.

[39]  M. Hoffmann,et al.  A Multibasic Cleavage Site in the Spike Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells , 2020, Molecular Cell.

[40]  J. Bloom,et al.  Protocol and Reagents for Pseudotyping Lentiviral Particles with SARS-CoV-2 Spike Protein for Neutralization Assays , 2020, bioRxiv.

[41]  P. Hotez,et al.  Potential for developing a SARS-CoV receptor-binding domain (RBD) recombinant protein as a heterologous human vaccine against coronavirus infectious disease (COVID)-19 , 2020, Human vaccines & immunotherapeutics.

[42]  Zacharias E. Andreadakis,et al.  The COVID-19 vaccine development landscape , 2020, Nature Reviews Drug Discovery.

[43]  I. Wilson,et al.  A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV , 2020, Science.

[44]  Lu Lu,et al.  Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion , 2020, Cell Research.

[45]  Linqi Zhang,et al.  Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor , 2020, Nature.

[46]  K. Shi,et al.  Structural basis of receptor recognition by SARS-CoV-2 , 2020, Nature.

[47]  Shibo Jiang,et al.  Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine , 2020, Cellular & Molecular Immunology.

[48]  A. Walls,et al.  Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein , 2020, Cell.

[49]  Qiang Zhou,et al.  Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2 , 2020, Science.

[50]  Shibo Jiang,et al.  Subunit Vaccines Against Emerging Pathogenic Human Coronaviruses , 2020, Frontiers in Microbiology.

[51]  B. Graham,et al.  Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation , 2020, Science.

[52]  P. Carmeliet,et al.  PHD1 controls muscle mTORC1 in a hydroxylation-independent manner by stabilizing leucyl tRNA synthetase , 2020, Nature Communications.

[53]  Zhènglì Shí,et al.  Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody , 2020, bioRxiv.

[54]  Barney S. Graham,et al.  Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen , 2017, Proceedings of the National Academy of Sciences.

[55]  Jui-Yi Chen,et al.  Nanoparticle Vaccines Adopting Virus-like Features for Enhanced Immune Potentiation , 2017, Nanotheranostics.

[56]  A. Jungbauer,et al.  Quantification and characterization of virus-like particles by size-exclusion chromatography and nanoparticle tracking analysis. , 2017, Journal of chromatography. A.

[57]  D. Agard,et al.  MotionCor2: anisotropic correction of beam-induced motion for improved cryo-electron microscopy , 2017, Nature Methods.

[58]  David J. Fleet,et al.  cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination , 2017, Nature Methods.

[59]  D. Burton,et al.  Presenting native-like trimeric HIV-1 antigens with self-assembling nanoparticles , 2016, Nature Communications.

[60]  S. J. Sucheck,et al.  Recent Advances in Subunit Vaccine Carriers , 2016, Vaccines.

[61]  U. Baxa,et al.  Structural and molecular basis for Ebola virus neutralization by protective human antibodies , 2016, Science.

[62]  D. Burton,et al.  Isolation of potent neutralizing antibodies from a survivor of the 2014 Ebola virus outbreak , 2016, Science.

[63]  Barney S. Graham,et al.  Pre-fusion structure of a human coronavirus spike protein , 2016, Nature.

[64]  R. Schwartz,et al.  Development of a mammalian cell culture process for rapid Clinical-Scale production of novel Influenza Nanoparticle vaccines , 2015, BMC Proceedings.

[65]  R. Rappuoli,et al.  Self-assembling protein nanoparticles in the design of vaccines , 2015, Computational and Structural Biotechnology Journal.

[66]  Shixia Wang,et al.  Identification of QS-21 as an Inflammasome-activating Molecular Component of Saponin Adjuvants* , 2015, The Journal of Biological Chemistry.

[67]  N. Grigorieff,et al.  CTFFIND4: Fast and accurate defocus estimation from electron micrographs , 2015, bioRxiv.

[68]  John P. Moore,et al.  Presenting native-like HIV-1 envelope trimers on ferritin nanoparticles improves their immunogenicity , 2015, Retrovirology.

[69]  J. Mascola,et al.  Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection , 2015, Nature Medicine.

[70]  U. Baxa,et al.  Rational Design of an Epstein-Barr Virus Vaccine Targeting the Receptor-Binding Site , 2015, Cell.

[71]  I. Carletti,et al.  Vaccine Adjuvant Systems containing monophosphoryl lipid A and QS-21 induce strong humoral and cellular immune responses against hepatitis B surface antigen which persist for at least 4 years after vaccination. , 2015, Vaccine.

[72]  N. Petrovsky,et al.  Severe Acute Respiratory Syndrome-Associated Coronavirus Vaccines Formulated with Delta Inulin Adjuvants Provide Enhanced Protection while Ameliorating Lung Eosinophilic Immunopathology , 2014, Journal of Virology.

[73]  H. Fausther-Bovendo,et al.  Pre-existing immunity against Ad vectors , 2014, Human vaccines & immunotherapeutics.

[74]  S. Morikawa,et al.  Effects of Toll-Like Receptor Stimulation on Eosinophilic Infiltration in Lungs of BALB/c Mice Immunized with UV-Inactivated Severe Acute Respiratory Syndrome-Related Coronavirus Vaccine , 2014, Journal of Virology.

[75]  J. Whittle,et al.  Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies , 2013, Nature.

[76]  I. Toth,et al.  Modern Subunit Vaccines: Development, Components, and Research Opportunities , 2013, ChemMedChem.

[77]  Sjors H.W. Scheres,et al.  RELION: Implementation of a Bayesian approach to cryo-EM structure determination , 2012, Journal of structural biology.

[78]  R. Couch,et al.  Immunization with SARS Coronavirus Vaccines Leads to Pulmonary Immunopathology on Challenge with the SARS Virus , 2012, PloS one.

[79]  F. Buonaguro,et al.  Effects of adjuvants on IgG subclasses elicited by virus-like Particles , 2012, Journal of Translational Medicine.

[80]  Ray Cummings,et al.  Vaccine stabilization: research, commercialization, and potential impact. , 2011, Vaccine.

[81]  Cheolju Lee,et al.  The crystal structure of ferritin from Helicobacter pylori reveals unusual conformational changes for iron uptake. , 2009, Journal of molecular biology.

[82]  Erin E. Thacker,et al.  Strategies to overcome host immunity to adenovirus vectors in vaccine development , 2009, Expert review of vaccines.

[83]  Debra Kristensen,et al.  Opportunities and challenges of developing thermostable vaccines , 2009, Expert review of vaccines.

[84]  G. Leroux-Roels,et al.  Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers. , 2008, Vaccine.

[85]  Jaap Goudsmit,et al.  Human Monoclonal Antibody Combination against SARS Coronavirus: Synergy and Coverage of Escape Mutants , 2006, PLoS medicine.

[86]  J. Peter-Katalinic,et al.  Glycoproteomics of N‐glycosylation by in‐gel deglycosylation and matrix‐assisted laser desorption/ionisation‐time of flight mass spectrometry mapping: Application to congenital disorders of glycosylation , 2005, Proteomics.

[87]  Conrad C. Huang,et al.  UCSF Chimera—A visualization system for exploratory research and analysis , 2004, J. Comput. Chem..

[88]  D. Lefeber,et al.  Th1-Directing Adjuvants Increase the Immunogenicity of Oligosaccharide-Protein Conjugate Vaccines Related to Streptococcus pneumoniae Type 3 , 2003, Infection and Immunity.

[89]  P. S. Kim,et al.  Crystal structure of GCN4-pIQI, a trimeric coiled coil with buried polar residues. , 1998, Journal of molecular biology.

[90]  E. Heinicke,et al.  Quantitative dot-blot assay for proteins using enhanced chemiluminescence. , 1992, Journal of immunological methods.

[91]  C. Dolea,et al.  World Health Organization , 1949, International Organization.

[92]  G K Gilbert,et al.  THE ORIGIN OF HYPOTHESES, ILLUSTRATED BY THE DISCUSSION OF A TOPOGRAPHIC PROBLEM. , 1896, Science.

[93]  Chun-Xia Zhao,et al.  Nanoparticle vaccines. , 2014, Vaccine.

[94]  Wen Jiang,et al.  EMAN2: an extensible image processing suite for electron microscopy. , 2007, Journal of structural biology.